point, the children’s depression rating scale (CDRS-R; P = 0.10), but this was not mentioned in the abstract. This and the small or absent advantages of fluoxetine on other end points (table) and in other studies, 3 shows that fluoxetine, like all other antidepressants, is of doubtful clinical importance for children. Adverse events and suicidal behaviour may be greater than the TADS paper says. Despite small numbers, more subjects leaving the study than reporting adverse effects, and the splitting of adverse events into multiple groups, significantly more psychiatric adverse events occurred in the fluoxetine group than the placebo group (